Meadows teases Trump action on immigration, China, prescription drugs

White House chief of staff Mark MeadowsMark Randall MeadowsThe Hill's 12:30 Report: Trump holds his last turkey pardon ceremony Overnight Defense: Pentagon set for tighter virus restrictions as top officials tests positive | Military sees 11th COVID-19 death | House Democrats back Senate language on Confederate base names Trump administration revives talk of action on birthright citizenship MORE on Monday teased forthcoming executive action from President TrumpDonald John TrumpMinnesota certifies Biden victory Trump tells allies he plans to pardon Michael Flynn: report Republican John James concedes in Michigan Senate race MORE targeting immigration, China and prescription drug pricing.

"Starting this week, you’ll see executive orders, you’ll see business that actually goes forward from the Oval Office when Congress doesn’t act," Meadows told "Fox & Friends."

Meadows, who was giving his first televised interview since taking the job in March, offered few specifics on each of the orders or when they would be signed.


The president would be looking to address the United States's manufacturing relationship with China to ensure American workers are prioritized, Meadows said.

Trump was also expected to sign action on immigration. The president last month signed an executive order suspending certain work visas for the remainder of the year.

And the president is expected to focus at least one executive order on prescription drugs, Meadows said. The White House has backed congressional efforts to low drug prices, but the odds of legislation passing this year decreased in recent days.

Sen. Chuck GrassleyCharles (Chuck) Ernest GrassleyRep. Rick Allen tests positive for COVID-19 On The Money: Biden to nominate Yellen for Treasury secretary | 'COVID cliff' looms | Democrats face pressure to back smaller stimulus Loeffler to continue to self-isolate after conflicting COVID-19 test results MORE (R-Iowa) is preparing to introduce an updated version of a Senate bill on the issue, but no Democrats are co-sponsoring it, sinking already slim hopes that there would be a bipartisan breakthrough.